Saxenda week one: what the first seven days actually look like

What did @itsjessicataylor_ actually say?

She reported losing ten pounds in her first week on Saxenda (liraglutide), admitted skipping a dose mid-week because she was sick, and then announced she was self-escalating from the starting dose to 1.2 mg. She also mentioned her blood sugar dropped "pretty bad" over the weekend and described the nausea as manageable.

To her credit, she flagged the dose skip and tried to contextualize the number. She said "let me clarify" before explaining the illness, which shows some self-awareness. But the leap from "I felt sick, skipped a dose, felt better" to "I'm moving up to 1.2" is exactly the kind of reasoning that gets people into trouble with GLP-1 medications.

Does the science back this up?

Ten pounds in one week sounds dramatic, but for someone with significant water retention or high sodium intake, early weight loss on a GLP-1 can include a substantial fluid component. The clinical trial data tells a more measured story.

In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), participants on liraglutide 3.0 mg lost an average of 8.4 kg over 56 weeks compared to 2.8 kg for placebo. Week-one losses were not the headline. A 10-pound drop in seven days almost certainly includes water weight, reduced food volume in the gut, and possibly some glycogen depletion, not just fat loss. Expecting that pace to continue is not realistic and sets up disappointment.

On the blood sugar comment: liraglutide is a GLP-1 receptor agonist approved for weight management in non-diabetic patients and for type 2 diabetes management. In people without diabetes, clinically significant hypoglycemia from liraglutide alone is uncommon. A blood sugar drop "pretty bad" in a non-diabetic user warrants a conversation with a prescriber, not a dose escalation.

What did they get wrong (or right)?

The dose escalation decision is the most concerning part of this video. Saxenda has a structured titration protocol: patients start at 0.6 mg daily for one week, then increase by 0.6 mg each week until reaching the maintenance dose of 3.0 mg. This schedule exists specifically to reduce gastrointestinal side effects. Skipping a dose due to illness, then feeling better, then jumping to 1.2 mg is not how the protocol works, and she essentially admits this might be a mistake mid-sentence.

She also casually mentioned a blood sugar drop severe enough to notice over a weekend. That detail got about four seconds of airtime before she moved on. For a non-diabetic patient on a GLP-1, that deserves more than a passing mention. It should be reported to the prescribing provider.

What she got right: she disclosed the dose skip and she was upfront that the ten-pound number might be misleading. That transparency matters in a genre where creators routinely post scale numbers with no context at all.

What should you actually know?

GLP-1 medications like liraglutide are serious prescription drugs with real side effects and real dosing protocols. They are not supplements you self-titrate based on how you felt this week.

• The Saxenda titration schedule is not optional. It was designed based on clinical tolerability data. Skipping steps increases the risk of nausea, vomiting, and discontinuation.
• Early weight loss on any GLP-1 is heavily influenced by water weight and reduced caloric intake, not just fat loss. Studies consistently show peak fat loss happens over months, not days.
• A blood sugar drop significant enough to notice, especially in someone not diagnosed with diabetes, should be documented and shared with a prescriber before any dose change.
• Week-one results are not predictive of long-term outcomes. The SCALE trial data shows meaningful weight loss requires sustained use over months with consistent titration.

If you are on Saxenda or any GLP-1 medication, your dose escalation decisions should be made with the provider who prescribed it, not based on how your week went. Social media is useful for community support. It is not a substitute for clinical oversight.